Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NexImmune Inc.

www.neximmune.com

Latest From NexImmune Inc.

Venture Funding Deals: BioNTech's Big Money Leads January Financings

BioNTech's $270m Series A round was the biggest start-up financing in January, but sizeable rounds also were raised by Centrexion ($67m), Eureka ($60m) and Pandion ($58m).

StartUps and SMEs Financing

Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan

Gossamer Bio, led by former Receptos CEO Faheem Hasnain and CMO Sheila Gujrathi, revealed $100m in seed and Series A funding during a week in which 17 companies revealed VC rounds totaling $891.2m, giving them good news to discuss during the J.P. Morgan Healthcare conference.

Business Strategies Financing

What Could Come After CAR-T? Cue Is Betting On Selective Biologics

Emerging Company Profile: Cue Biopharma, a young biotech formed on the basis of research from the Albert Einstein College of Medicine, is developing biologics engineered to selectively modulate disease-relevant T-cells to treat cancer – technology it has called the "next wave" in cancer immunotherapy.

StartUps and SMEs ImmunoOncology

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NexImmune Inc.
  • Senior Management
  • Scott Carmer, CEO
    Alain Cappeluti, CFO
    Kristi Jones, COO
  • Contact Info
  • NexImmune Inc.
    Phone: (301) 685-1688
    9119 Gaither Rd.
    Gaithersburg, MD 20877
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register